Company Description
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Jeremy Gowler |
Contact Details
Address: 1601 Trapelo Road, Suite 178 Waltham, Massachusetts 02451 United States | |
| Phone | (781) 819-0080 |
| Website | adagiotx.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Hering M.B.A. | Chief Executive Officer and Director |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| William E. Duke Jr., M.B.A. | Chief Financial Officer |
| Jeremy Gowler | Chief Operating Officer and Chief Commercial Officer |
| Stacy Price M.S. | Chief Technology and Manufacturing Officer |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Scott Young | Senior Vice President of Investor Relations and Corporate Communications |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Heidi Spurling M.S. | Vice President of Strategy and Operations and Chief of Staff to the Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | 144 | Filing |
| May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 19, 2024 | EFFECT | Notice of Effectiveness |
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 8-K | Current Report |